Document is current
Any future updates will be listed below
-
Authors
Yang, Mengling
Yao, Jingyu https://orcid.org/0009-0008-4717-6018
Jia, Lin
Kocab, Andrew J. https://orcid.org/0000-0001-6069-2166
Zacks, David N.
-
Funding
Funding for this research was provided by:
ONL Therapeutics
U.S. Department of Health & Human Services | NIH | National Eye Institute (EY-07003, EY-07003, EY-07003)
- License Information
-
More Information
Article History
Received: 26 March 2025
Revised: 16 May 2025
Accepted: 12 June 2025
First Online: 1 July 2025
Competing interests
: Two of the authors have relevant disclosures. AJK is an employee of ONL Therapeutics, the company that produces ONL1204. DNZ is an employee of the University of Michigan and is also a co-founder of ONL Therapeutics. DNZ also holds patents through the University of Michigan that are licensed to ONL Therapeutics. DNZ laboratory receives grant funding from ONL Therapeutics. All other authors have no competing interests.
: All animal experiments and experimental methods were performed in accordance with the guidelines set forth by the University of Michigan Animal Care Committee and conformed to the Use of Animals in Ophthalmology and Vision Research established by the Association for Research in Vision and Ophthalmology (ARVO).
